Bone Cancer Archives - Page 2 of 26 - Cancer Therapy Advisor

Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.

A New Trend in Drug Development: Leveraging Data from Expanded Access

By

March 2, 2020

Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.

New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.

General Oncology

Evidence Suggests B Cells Play a Role in Immunotherapy Response

By

Sarah Elizabeth Richards

February 24, 2020

New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.

Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.

General Oncology

The Questionable Practice That Permeates Oncology Clinical Trials

By

Christina Bennett, MS

February 19, 2020

Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.

Bone Cancer

Strontium89 Now Available for Relief of Metastatic Bone Pain

By

Diana Ernst, RPh

February 14, 2020

Strontium89 (Strontium Chloride Sr-89 injection), a radiopharmaceutical indicated for the relief of bone pain in patients with painful skeletal metastases, has been made available by Q BioMed.

Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.

General Oncology

Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life

By

Helene Engler, PhD

February 13, 2020

Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.

The cancer field is not immune to the challenges of out-of-network and surprise billing.

General Oncology

The Unexpected Costs of Cancer Treatment: Out-of-Network Billing

By

Amber Dance, PhD

February 4, 2020

The cancer field is not immune to the challenges of out-of-network and surprise billing.

Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.

General Oncology

The FDA Approval Process Needs Refinement, Not a Total Overhaul

By

Randi Hernandez

January 14, 2020

Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.